|
|
|
|
|
|
|
03.06.26 - 23:48
|
Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders′ Meeting (Business Wire)
|
|
|
All Resolutions Proposed to Shareholders PassedPIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) (the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced that all resolutions proposed to the shareholders at the Ordinary and Extraordinary Meeting of Shareholders (“Shareholders' Meeting”) held virtually on May 26, 2026, have passed.
Details of the resolutions submitted to, and approved by, the Shareholders' Meeting are included in the explanatory report prepared by the Board of Directors of the Company, which is available on the Company's corporate website at https://ir.stevanatogroup.com/.
Shareholders approved, among other things, the annual financial statements for the financial year ended on December 31, 2025 and the allocation of annual net profits for the year, including a distribution of dividends in the amount of EUR 0.054 for each outst...
|
|
|
|
|
|
|
|
|
|
|
03.06.26 - 23:15
|
Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures (The Newswire)
|
|
|
Vancouver, British Columbia – TheNewswire - 3 June, 2026 – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCF”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, announces that it has closed a non-brokered private placement (the “Offering”) of unsecured convertible debentures of the Company (each, a “Convertible Debenture”). The Company issued 3,673 Convertible Debentures for aggregate gross proceeds of C$3,673,000 pursuant to the Offering.
The principal amount and any unpaid accrued interest of the Convertible Debentures will be due and payable 14 months from the closing date of the private placement (the “Maturity Date”). Each Convertible Debenture will bear interest at 25.00% per annum, calculated on a simple interest basis. If the Convertible Debentures are not repaid on or prior to the Maturity Date, the outstanding principal amount of the Convertible Deben...
|
|
|
|
|
|
|
03.06.26 - 22:33
|
Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire EN)
|
|
|
NOVATO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's president and chief executive officer will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 4:00 PM ET....
|
|
|
03.06.26 - 22:33
|
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting (GlobeNewswire EN)
|
|
|
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 17, 2026, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET....
|
|
|
|
|
|
|
|
|
|
|
|
|
03.06.26 - 21:42
|
Corporate News: Amgen (EQS)
|
|
|
EUROPÄISCHE KOMMISSION ERTEILT ZULASSUNG FÜR IMDYLLTRA® VON AMGEN FÜR DIE BEHANDLUNG VON KLEINZELLIGEM LUNGENKREBS IM FORTGESCHRITTENEN STADIUM...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
